Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings

The reported revenue represents a surprise of +5.72% over the Zacks Consensus Estimate of $650.3 million. With the consensus EPS estimate being $0.98, the EPS surprise was +8.16%. Neurocrine Biosciences (NBIX) reported $687.5 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $1.06 for the same period compares to $0.63 a year ago. Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected ...